Guidelines
COVID-19 - Inpatient Therapies

COVID-19 - Inpatient Therapies

Initial Considerations

Inclusion Criteria:

  • Positive for COVID-19 Infection, AND
  • Requiring hospitalization due to COVID-19 Infection

Clinical suspicion would include:

  • Fever ≥100.4°F for ≥3 days (OR fever ≥100.4°F for ≥24 hours with signs of shock/critical illness)
  • No alternative plausible diagnosis

AND any one of the following

  • GI: abdominal pain, diarrhea, vomiting
  • CV: chest pain, arrhythmia, signs of shock, hypotension
  • Mucocutaneous: rash, oral changes, conjunctivitis, extremity swelling/peeling
  • Resp: cough, shortness of breath, difficulty breathing
  • Neuro: altered mental status, headache, irritability

Bolded symptoms are most common presenting symptoms

Additional Information

Refer to CT Children s COVID-19 Intranet site, under Care for COVID-19 Patient for more resources

Contacts

  • Kenneth Banasiak, MD
  • Heather Schlott, MD
  • John Schreiber, MD
  • Grace Hong, APRN
  • Jennifer Girotto, PHARMD

Last updated: 03/03/2022

  1. Murthy S, Gomersall CD, Fowler RA. Care for critically patients with COVID-19. JAMA. 2020.
    Mar;doi:10.1001/jama.2020.3633[Epub ahead of print].
  2. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease. (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.
  3. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar;14(1):72-73.
  4. Colson P, Rolain JM, Lagier JC, et. al. Chloroquine and hydroxychloroquine as available
    weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Mar; doi:10.1016/j.ijantimicag.2020.105932 [Epub ahead of print].
  5. Gautret P, Lagier JC, Parola P, et. al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar; doi:10.1016/j.ijantimicag.2020.105949 [Epub ahead of print].
  6. Zhai P , Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents. 2020 Mar; doi:10.1016/j.ijantimicag.2020.105955 [Epub ahead of print].
  7. Chu CM, Cheng VC, Hung IF, et. al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59 (3): 252-256.
  8. Cao B, Wang Y, Wen D, et. al. A trial of lopinavir–ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020 Mar 18; doi:10.1056/NEJMoa2001282 [Epub ahead of print].
  9. Gilead Sciences Update On The Company’s Ongoing Response To COVID-19. https://www.gilead.com/purpose/advancing-global-health/covid-19.
  10. Cron RQ, Chatham WW. The rheumatologist’s role in COVID-19. J Rheumatol. 2020 Mar; doi:10.3899/jrheum200334 [Epub ahead of print].
  11. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
  12. Vaduganathan, M, Vardeny O, Michel T,et al. Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19. N Engl J Med. 2020 Mar; doi:10.1056/NEJMsr2005760 [Epub ahead of print].
  13. Zhou F, Yu T, Du R, et. al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar;395:1054-62.
  14. Wu C, Chen X, Cai Y, et. al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar; doi:10.1001/jamainternmed.2020.0994 [Epub ahead of
    print].
  15. Xia W, Shao J, Guo Y, et. al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults. Pediatr Pulmonol. 2020 Mar; doi:10.1002/ppul.24718 [Epub ahead of print].
  16. Pan C, Chen L, Cong Lu C, et. al. Lung Recruitability in SARS-CoV-2 Associated Acute Respiratory Distress Syndrome: A Single-center, Observational Study. Am J Respir Crit Care Med. 2020 Mar; doi:10.1164/rccm.202003-0527LE [Epub ahead of print].
  17. NIH Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/.